secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001104659-23-115796
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Therapeutics prices $200.5M public offering of 7.425M shares at $27.00
------------------------------------------------------------------------------

- Offering of 7,425,000 shares at $27.00 per share; underwriters have 30-day option for 1,113,750 additional shares.
- Net proceeds expected ~$188.3M after discounts and expenses.
- Proceeds to fund clinical/preclinical development including barzolvolimab and bispecific antibody platform.
- Offering expected to close on or about Nov 10, 2023; Jefferies and Leerink Partners lead the underwriting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465923115796/0001104659-23-115796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465923115796/tm2330052d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer